Policy | December 04, 2025
Promotion of indigenous pharmaceutical manufacturing
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
The stability is led by healthy demand in the domestic and emerging markets
The govt has rolled out three schemes for promoting the manufacture of API
Subscribe To Our Newsletter & Stay Updated
